>Still 4/4 is jaw dropping, especially measured against the increasing effectiveness as they escalated the dose, and they aren't done escalating yet.<
According to page 22 of the Daiichi's presentation you provided the other day (thank you!), the Dose Expansion Cohort started already in July, 2019. Could it be the dose escalating is complete and has been analyzed as a dose level based on MDT would be needed for the expansion cohort, yes?
If so, I could see this being either a negative or a positive...toxity/AE's were significant enough to determine a MTD and to select a lower dose level than say for example 8mg, or alternatively, results are so stellar/jaw dropping at the 8mg level, why continue dose escalation. Don't know, just trying to reconcile DS's presentation with the no abstract.
Other possibility is nothing new to report when the late Abstracts were due...no clue...